Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN1910 SAD in Healthy Adults
NCT05307978Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Apr 2022
- Primary completion
- Feb 2023
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ALXN1910 in hypophosphatasia (HPP) (6 cohorts), sponsored by Alexion Pharmaceuticals. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events. Started Apr 2022; status: completed.
02
Drugs
ALXN1910
03
Conditions
hypophosphatasia (HPP)
Beyond the preview
Go deeper on NCT05307978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05307978.